ReviewInternational wound journal2019
Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.
Review in International wound journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Targeted therapy for immune mediated skin diseases. What should a dermatologist know?Anais brasileiros de dermatologiaPooled it
- IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?Journal of clinical medicine · 2026Review
- Pyoderma Gangrenosum Following Cesarean Section: A Case Report With Individualized Management.Case reports in obstetrics and gynecology · 2026Article
- Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor.Frontiers in immunology · 2026Article
- The diagnostic and therapeutic challenges of pyoderma gangrenosum in a 32-year-old woman with systemic lupus erythematosus: a case report.Annals of medicine and surgery (2012) · 2025Article
- Inflammatory Skin Diseases: The Importance of Immunological Signatures.Deutsches Arzteblatt international · 2025Review
- Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?Archives of dermatological research · 2025Review
- Secukinumab treatment in a pediatric patient with corticosteroid-intolerant pyoderma gangrenosum: a case report.Frontiers in medicine · 2025Article
- [Application of advanced treatment in chronic inflammatory bowel diseases].Innere Medizin (Heidelberg, Germany) · 2025Review
- Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review.Rheumatology international · 2024Review
- Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review.Journal of clinical medicine · 2024Review
- Pyoderma Gangrenosum, a Challenging Postpartum Diagnosis-Case Report and Literature Review.Journal of clinical medicine · 2024Review
- What is your diagnosis?Journal of the Turkish German Gynecological Association · 2024Article
- The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives.International journal of molecular sciences · 2024Review
- New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.The Journal of dermatology · 2024Review
- Treatment Strategies in Neutrophilic Dermatoses: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Pyoderma Gangrenosum: Treatment Options.Drugs · 2023Review
- Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.American journal of clinical dermatology · 2022Review
- Multiple Lesions at Different Stages of Pyoderma Gangrenosum in a Crohn's Disease Patient.Clinical, cosmetic and investigational dermatology · 2022Article
- Atypical Forms of Pyoderma Gangrenosum in Inflammatory Bowel Disease: Report of Four Cases and Literature Review.International medical case reports journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNFα inhibitors in adults with PG. A literature search including databases such as PubMed, Embase, Scopus, and Web of Science was conducted, using search terms related to PG and TNFα inhibitors. Studies and case reports were included if patients were diagnosed with PG, over the age of 18 and administered TNFα inhibitor. A total of 3212 unique citations were identified resulting in 222 articles describing 356 patients being included in our study. The study we report found an 87% (95% CI: 83%-90%) response rate and a 67% (95% CI: 62%-72%) complete response rate to TNFα inhibitors. No statistically significant differences in the response rates (P = 0.6159) or complete response rates (P = 0.0773) to infliximab, adalimumab, and etanercept were found. In our study TNFα inhibitors demonstrated significant effectiveness with response and complete response rates supporting the use of TNFα inhibitors to treat PG in adults. Our study suggests that there is no significant difference in effectiveness among infliximab, adalimumab, and etanercept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.